Peptilogics

Peptilogics is a private, clinical-stage biotechnology company pioneering a new class of anti-biofilm therapeutics to address devastating medical device-related infections. Its lead candidate, PLG0206, is an engineered peptide with Orphan Drug, Fast Track, and QIDP designations, currently enrolling a pivotal Phase 2/3 trial (RETAIN) for prosthetic joint infections (PJI), where no approved therapies exist. The company leverages a proprietary platform for peptide engineering to target biofilm-forming pathogens, positioning itself in a large, underserved market with high clinical and economic burden. Leadership includes a mix of scientific founders and seasoned drug development executives.

Proprietary engineered peptide platform for developing broad-spectrum anti-biofilm therapeutics designed to disrupt bacterial biofilms on medical devices.

Direct competition for an approved PJI therapy is currently minimal, but the standard of care (multiple surgeries and long-term antibiotics) is well-established. Other companies are investigating anti-biofilm strategies, including novel antibiotics, bacteriophages, and surface coatings for implants, creating a broader competitive environment in the fight against device-related infections.